These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 11187882

  • 1. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D, Reyes H, Felch M, Sakurai Y.
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [Abstract] [Full Text] [Related]

  • 2. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP.
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [Abstract] [Full Text] [Related]

  • 3. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain.
    Laub R, Di Giambattista M, Fondu P, Brackmann HH, Lenk H, Saenko EL, Felch M, Scandella D.
    Thromb Haemost; 1999 Jan; 81(1):39-44. PubMed ID: 9974372
    [Abstract] [Full Text] [Related]

  • 4. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
    van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, Mauser-Bunschoten EP, Aalberse RC, Vidarsson G, Voorberg J.
    Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
    [Abstract] [Full Text] [Related]

  • 5. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA, Levin LG, Harrison JA, DePianto DJ, Suzuki CM, Ziaja CL, Brown JE, Jolly KW, Reisner HM, Abildgaard CF, Powell JS.
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [Abstract] [Full Text] [Related]

  • 6. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L, Pitlik E.
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [Abstract] [Full Text] [Related]

  • 7. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors.
    Sakurai Y, Shima M, Tanaka I, Fukuda K, Yoshida K, Yoshioka A.
    Haematologica; 2004 Jun; 89(6):696-703. PubMed ID: 15194537
    [Abstract] [Full Text] [Related]

  • 8. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G, Kroner B, Immune Tolerance Study Group (ITSG).
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [Abstract] [Full Text] [Related]

  • 9. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors.
    Sawamoto Y, Prescott R, Zhong D, Saenko EL, Mauser-Bunschoten E, Peerlinck K, van den Berg M, Scandella D.
    Thromb Haemost; 1998 Jan; 79(1):62-8. PubMed ID: 9459325
    [Abstract] [Full Text] [Related]

  • 10. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P, Plamenová I, Hollý P, Stasko J.
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [Abstract] [Full Text] [Related]

  • 11. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM.
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [Abstract] [Full Text] [Related]

  • 12. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J.
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [Abstract] [Full Text] [Related]

  • 13. Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains.
    Chaves DG, Velloso-Rodrigues C, Moreau V, Nguyen C, Villard S, Belisário AR, Granier C, Santoro MM.
    Br J Haematol; 2008 May; 141(5):708-15. PubMed ID: 18422780
    [Abstract] [Full Text] [Related]

  • 14. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP.
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [Abstract] [Full Text] [Related]

  • 15. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M.
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [Abstract] [Full Text] [Related]

  • 16. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ, Fenske TS, Blinder MA.
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [Abstract] [Full Text] [Related]

  • 17. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A, Kavakli K, Baytan B, Kazanci E, Sayli T, Oren H, Celkan T, Gursel T.
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [Abstract] [Full Text] [Related]

  • 18. Novel therapies for immune tolerance in haemophilia A.
    Collins PW.
    Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
    [Abstract] [Full Text] [Related]

  • 19. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S, Sharifian RA, Khoshnoodi J, Karimi K, Milani M, Okita DK, Shokri F, Conti-Fine BM.
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [Abstract] [Full Text] [Related]

  • 20. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.
    Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM.
    J Clin Invest; 1996 Mar 15; 97(6):1382-8. PubMed ID: 8617869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.